𝔖 Bobbio Scriptorium
✦   LIBER   ✦

The Effects of 13-cis Retinoic Acid on Squamous Cell Carcinoma Proliferation and Adhesion to Extracellular Matrix Proteins

✍ Scribed by Matthew T. Speyer; Jon A. Jackson; Brian B. Burkey

Book ID
110079267
Publisher
John Wiley and Sons
Year
1997
Tongue
English
Weight
591 KB
Volume
107
Category
Article
ISSN
0023-852X

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

13-CIS retinoic acid and interferon-Ξ± Β±
13-CIS retinoic acid and interferon-Ξ± Β± irradiation in the treatment of squamous-cell carcinomas
✍ Wolfgang Hoffmann; Martina Schiebe; Peter Hirnle; Rainer Souchon; Michael Clemen πŸ“‚ Article πŸ“… 1997 πŸ› John Wiley and Sons 🌐 French βš– 43 KB πŸ‘ 1 views

Pre-clinical data indicate that retinoid/interferon combinations have significant activity in modulating malignant cell growth, differentiation and programmed cell death in different hematologic and solid tumor systems . Clinically, the combination of 13-cis retinoic acid (13cRA) and interferon-a (I

Effects of Ξ²-all-trans retinoic acid on
Effects of Ξ²-all-trans retinoic acid on growth, proliferation, and cell death in a multicellular tumor spheroid model for squamous carcinomas
✍ Peter G. Sacks; Victor Oke; Tracey Vasey; Dennise P. Calkins; Nicholas H. A. Ter πŸ“‚ Article πŸ“… 1990 πŸ› John Wiley and Sons 🌐 English βš– 820 KB

## Abstract The growth of multicellular tumor spheroids, MTSs, from squamous carcinoma line MDA 886Ln was inhibited by β‐all‐trans retinoic acid (RA). Inhibition occurred within 3 to 5 days of treatment, and MTS size then remained static for up to 2 weeks. Although their growth stopped, 10‐day‐trea

Induction of cell cycle arrest and apopt
Induction of cell cycle arrest and apoptosis by a combined treatment with 13-cis-retinoic acid, interferon-Ξ±2a, and Ξ±-tocopherol in squamous cell carcinoma of the head and neck
✍ Xin Zhang; Zhuo (Georgia) Chen; Fadlo R. Khuri; Dong M. Shin πŸ“‚ Article πŸ“… 2007 πŸ› John Wiley and Sons 🌐 English βš– 497 KB

## Abstract ## Background. We have previously conducted phase II trials with a combination of 13‐__cis__‐retinoic acid (13‐cRA), interferon‐α2a (IFN‐α2a), and α‐tocopherol (α‐TF) in patients with advanced oral premalignant lesions and locally advanced head and neck cancer in the adjuvant settings